title: Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network.
abstract: BACKGROUND
  Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described.
  
  
  OBJECTIVE
  To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetine hepatotoxicity.
  
  
  METHODS
  Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensive laboratory and clinical evaluation to exclude competing aetiologies of liver injury as well as a standardized assessment for causality and disease severity.
  
  
  RESULTS
  Between 1/2006 and 9/2009, six of the seven cases of DILI attributed to duloxetine were assessed as definite or very likely. Median patient age was 49 years, six (86%) were women and the median latency from drug initiation to DILI onset was 50 days. Six patients developed jaundice and the median peak alanine aminotransferase in the five patients with acute hepatocellular injury was 1633 IU/L. Ascites developed in one patient and acute renal dysfunction in two others (29%). All patients recovered without liver transplantation even though three had pre-existing chronic liver disease. Liver histology in four cases demonstrated varying patterns of liver injury.
  
  
  CONCLUSIONS
  Duloxetine hepatotoxicity developed within 2 months of drug intake and led to clinically significant liver injury. A spectrum of laboratory, histological and extra-hepatic features were noted at presentation.
authors.affiliation: Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
authors.forename: R
authors.initials: R
authors.lastname: Vuppalanchi
authors.forename: P H
authors.initials: PH
authors.lastname: Hayashi
authors.forename: N
authors.initials: N
authors.lastname: Chalasani
authors.forename: R J
authors.initials: RJ
authors.lastname: Fontana
authors.forename: H
authors.initials: H
authors.lastname: Bonkovsky
authors.forename: R
authors.initials: R
authors.lastname: Saxena
authors.forename: D
authors.initials: D
authors.lastname: Kleiner
authors.forename: J H
authors.initials: JH
authors.lastname: Hoofnagle
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013876:Thiophenes / Q000009:adverse effects*
chemical_list: D000928:Antidepressive Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride
references.citation: Hum Psychopharmacol. 2009 Jul;24(5):401-8
references.pmid: 19526453
references.citation: Clin Ther. 2005 Aug;27(8):1126-43
references.pmid: 16199241
references.citation: Clin Gastroenterol Hepatol. 2006 Jul;4(7):912-7
references.pmid: 16797245
references.citation: Curr Drug Saf. 2008 May;3(2):143-53
references.pmid: 18690992
references.citation: Am Rev Respir Dis. 1978 Sep;118(3):461-6
references.pmid: 707874
references.citation: Drug Saf. 2009;32(1):55-68
references.pmid: 19132805
references.citation: J Clin Psychiatry. 2003 Dec;64(12):1465-75
references.pmid: 14728109
references.citation: J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S34-9
references.pmid: 14562856
references.citation: Am Rev Respir Dis. 1986 Oct;134(4):666-8
references.pmid: 3767121
references.citation: Am Rev Respir Dis. 1978 Jun;117(6):991-1001
references.pmid: 666111
references.citation: Arch Gen Psychiatry. 2005 Jun;62(6):593-602
references.pmid: 15939837
references.citation: Clin Pediatr (Phila). 2001 May;40(5):243-8
references.pmid: 11388672
references.citation: Curr Med Res Opin. 2007 Jan;23(1):175-84
references.pmid: 17257478
references.citation: Hepatology. 2010 Jun;51(6):2117-26
references.pmid: 20512999